The Compliance Choice: Audit-Proof Your GLP-1 Inventory: The “Digital Birth Certificate” Solution

The Ozempic (semaglutide) multidistrict litigation (MDL 3094) has entered a high-stakes phase in 2026, with a sharpened focus on medical verification and emerging evidence linking the drug to permanent injuries.

1. Medical Evidence: NAION and Gastroparesis

New clinical data is driving the current litigation wave, shifting the focus from general side effects to specific, life-altering conditions:

• NAION (Vision Loss): A landmark study and subsequent research in 2025/2026 suggest that semaglutide users may face a significantly higher risk of Non-Arteritic Anterior Ischemic Optic Neuropathy. Often called an “eye stroke,” this condition causes sudden, irreversible vision loss due to restricted blood flow to the optic nerve.
• Verified Gastroparesis: While thousands of “stomach paralysis” claims have been filed, 2026 rulings now require objective medical testing. Plaintiffs must typically provide results from a Gastric Emptying Study (GES) to prove their diagnosis is medication-induced rather than a pre-existing diabetic complication.

2. Technology: Mohr Marketing’s AI WebTracker®

To navigate this stricter legal environment, Mohr Marketing has deployed its proprietary AI WebTracker® system. This tool is designed to solve the “quality vs. volume” problem in mass tort lead generation by:

• Filtering Claims: Using AI to identify high-value claimants who already have the necessary medical documentation (like GES results or NAION diagnoses).
• Fraud Detection: Utilizing “Scammer Scrub™” technology to eliminate bots and non-compliant leads, ensuring firms receive “audit-proof” retainers.
• MDL Readiness: Providing a “Digital Certificate of Origin” for every case to ensure 1-to-1 compliance and procedural integrity for bellwether trial selection.

3. Current Litigation Status (Feb 2026)

Legal Note: Cases involving NAION are currently estimated to have a higher potential settlement value (potentially $1M+) compared to temporary gastrointestinal issues due to the permanent nature of the injury.

Contact Mohr Marketing today to secure your exclusive, signed GLP-1 retainers and build a cleaner, more valuable docket.

Contact Mohr Marketing today to discuss our GLP-1 Availability.

Ready to fill your docket with valid cases?

Partner with Mohr Marketing to secure high-quality, compliant plaintiffs.

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Mohr Marketing Team

Summary

Article Name

2026 Ozempic Litigation Updates

Description

Avoid lead fraud with AI WebTracker® and Scammer Scrub™ verified GLP-1 cases. We deliver compliant, signed cases for gastroparesis and vision loss litigation.

Author

Mohr Marketing Team

Publisher Name

Mohr Marketing, LLC

Publisher Logo